Clinical Trials Logo

Clinical Trial Summary

There is no known definite treatment after exposure to SARS-CoV-2, but the some animal and clinical trials confirmed the efficacy of hydroxychloroquine (HCQ) or chloroquine against SARS-CoV-2. Thus, in this study, we aim to evaluate the efficacy and safety of hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2. - Primary end point: comparison the rate of COVID-19 between PEP with HCQ and control group. - Secondary end point: Comparison of the rate of COVID-19 according to the contact level (time, place, degree of wearing personal protective equipment). - Safety comparison: Safety verification by identifying major side effects in the HCQ group."


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04330144
Study type Interventional
Source Gangnam Severance Hospital
Contact
Status Withdrawn
Phase Phase 3
Start date April 1, 2020
Completion date June 29, 2020